利妥昔-话题@MedSci

#利妥昔#

179篇内容 | 3532人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660511, encodeId=975d1660511bf, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEPHRUTIX:安慰剂与利妥昔单抗对照评估微小病变型肾病综合征的T细胞亚群变化, objectType=article, longId=217184, objectId=b4eb21e184bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4eb21e184bb, replyNumber=0, likeNumber=84, createdTime=2022-03-08, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4eb21e184bb, moduleTitle=NEPHRUTIX:安慰剂与利妥昔单抗对照评估微小病变型肾病综合征的T细胞亚群变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4eb21e184bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660517, encodeId=1135166051e34, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Chest：利妥昔单抗治疗对耶氏肺孢子菌肺炎一级预防的效果分析, objectType=article, longId=220540, objectId=329a2205403d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=329a2205403d, replyNumber=0, likeNumber=107, createdTime=2022-03-27, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=329a2205403d, moduleTitle=Chest：利妥昔单抗治疗对耶氏肺孢子菌肺炎一级预防的效果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=329a2205403d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660528, encodeId=94e51660528f5, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JNNP:厄瓜利珠单抗与利妥昔单抗治疗全身性重症肌无力的比较, objectType=article, longId=300333, objectId=438830033364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=438830033364, replyNumber=0, likeNumber=77, createdTime=2022-05-31, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=438830033364, moduleTitle=JNNP:厄瓜利珠单抗与利妥昔单抗治疗全身性重症肌无力的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=438830033364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660523, encodeId=82461660523f7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Neurology：利妥昔单抗治疗乙酰胆碱受体抗体阳性重症肌无力的2期试验：安全、耐受性良好，但不可显著减少类固醇使用, objectType=article, longId=221575, objectId=e6ec2215e50a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6ec2215e50a, replyNumber=0, likeNumber=90, createdTime=2022-03-15, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6ec2215e50a, moduleTitle=Neurology：利妥昔单抗治疗乙酰胆碱受体抗体阳性重症肌无力的2期试验：安全、耐受性良好，但不可显著减少类固醇使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6ec2215e50a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660514, encodeId=4a181660514f4, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, objectType=article, longId=218141, objectId=54be2181415e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54be2181415e, replyNumber=0, likeNumber=83, createdTime=2022-06-02, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54be2181415e, moduleTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54be2181415e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660526, encodeId=942916605265f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, objectType=article, longId=295064, objectId=3d5529506462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d5529506462, replyNumber=0, likeNumber=97, createdTime=2022-02-23, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d5529506462, moduleTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d5529506462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660518, encodeId=e936166051843, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet Rheumatology: 利妥昔单抗对风湿性多肌痛患者的疗效：一项双盲、随机、安慰剂对照、概念验证试验, objectType=article, longId=220568, objectId=d05e220568ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d05e220568ed, replyNumber=0, likeNumber=77, createdTime=2022-03-25, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d05e220568ed, moduleTitle=Lancet Rheumatology: 利妥昔单抗对风湿性多肌痛患者的疗效：一项双盲、随机、安慰剂对照、概念验证试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d05e220568ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660504, encodeId=fae11660504d7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！, objectType=article, longId=215762, objectId=968f215e627f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968f215e627f, replyNumber=0, likeNumber=73, createdTime=2022-02-06, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968f215e627f, moduleTitle=J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968f215e627f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660524, encodeId=74ed16605248f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, objectType=article, longId=294056, objectId=900f294056ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=900f294056ec, replyNumber=0, likeNumber=84, createdTime=2022-10-31, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=900f294056ec, moduleTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=900f294056ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660525, encodeId=dab9166052543, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=BJD：超小剂量利妥昔单抗治疗天疱疮, objectType=article, longId=294970, objectId=45192949e0b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45192949e0b7, replyNumber=0, likeNumber=82, createdTime=2022-02-27, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45192949e0b7, moduleTitle=BJD：超小剂量利妥昔单抗治疗天疱疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45192949e0b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660508, encodeId=86291660508ef, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Clin Cancer Res：利妥昔单抗+来那度胺→来那度胺治疗惰性非霍奇金淋巴瘤的长期预后, objectType=article, longId=216893, objectId=aac0216893ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aac0216893ff, replyNumber=0, likeNumber=92, createdTime=2022-05-24, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aac0216893ff, moduleTitle=Clin Cancer Res：利妥昔单抗+来那度胺→来那度胺治疗惰性非霍奇金淋巴瘤的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aac0216893ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660501, encodeId=2d7a166050141, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM:利妥昔单抗vs吗替麦考酚酯治疗中重度寻常型天疱疮, objectType=article, longId=211617, objectId=97e321161e56, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97e321161e56, replyNumber=0, likeNumber=98, createdTime=2021-12-07, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97e321161e56, moduleTitle=NEJM:利妥昔单抗vs吗替麦考酚酯治疗中重度寻常型天疱疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97e321161e56)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660499, encodeId=6231166049992, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JASN：RI-CYCLO随机试验| 利妥昔单抗 vs 环磷酰胺治疗膜性肾病, objectType=article, longId=207877, objectId=a93a20e8776a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a93a20e8776a, replyNumber=0, likeNumber=0, createdTime=2021-07-12, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a93a20e8776a, moduleTitle=JASN：RI-CYCLO随机试验| 利妥昔单抗 vs 环磷酰胺治疗膜性肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a93a20e8776a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660510, encodeId=8dd1166051030, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效, objectType=article, longId=217177, objectId=f20e21e177df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f20e21e177df, replyNumber=0, likeNumber=81, createdTime=2021-12-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f20e21e177df, moduleTitle=Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f20e21e177df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660506, encodeId=d49116605063c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JCEM：利妥昔单抗在治疗Graves眼病患者中没有获益？, objectType=article, longId=216732, objectId=b3fe216e3245, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3fe216e3245, replyNumber=0, likeNumber=85, createdTime=2022-04-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3fe216e3245, moduleTitle=JCEM：利妥昔单抗在治疗Graves眼病患者中没有获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3fe216e3245)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660522, encodeId=43be1660522f6, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, objectType=article, longId=221413, objectId=18d1221413ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18d1221413ca, replyNumber=0, likeNumber=78, createdTime=2022-11-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18d1221413ca, moduleTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18d1221413ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660515, encodeId=ab0a1660515e6, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=CRAL:天疱疮治疗指南的比较：全身糖皮质激素、利妥昔单抗和其他免疫抑制疗法, objectType=article, longId=218624, objectId=a287218624b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a287218624b6, replyNumber=0, likeNumber=92, createdTime=2022-02-03, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a287218624b6, moduleTitle=CRAL:天疱疮治疗指南的比较：全身糖皮质激素、利妥昔单抗和其他免疫抑制疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a287218624b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660503, encodeId=392a166050363, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Cell：新生儿胆道闭锁发病机制被揭示，利妥昔单抗可能成为潜在治疗药物, objectType=article, longId=215750, objectId=dfaa215e5085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfaa215e5085, replyNumber=0, likeNumber=95, createdTime=2021-08-21, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfaa215e5085, moduleTitle=Cell：新生儿胆道闭锁发病机制被揭示，利妥昔单抗可能成为潜在治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfaa215e5085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660500, encodeId=220016605004c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫, objectType=article, longId=207605, objectId=7f8820e605f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8820e605f3, replyNumber=0, likeNumber=89, createdTime=2021-03-14, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8820e605f3, moduleTitle=J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8820e605f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660507, encodeId=2156166050ecb, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Kidney Int：糖皮质激素和环磷酰胺交替治疗原发性膜性肾病优于他克莫司和利妥昔单抗的序贯治疗, objectType=article, longId=216758, objectId=6f50216e58a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f50216e58a5, replyNumber=0, likeNumber=87, createdTime=2022-03-31, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f50216e58a5, moduleTitle=Kidney Int：糖皮质激素和环磷酰胺交替治疗原发性膜性肾病优于他克莫司和利妥昔单抗的序贯治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f50216e58a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEPHRUTIX:安慰剂与利妥昔单抗对照评估微小病变型肾病综合征的T细胞亚群变化

2022-03-08

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Chest：利妥昔单抗治疗对耶氏肺孢子菌肺炎一级预防的效果分析

2022-03-27

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JNNP:厄瓜利珠单抗与利妥昔单抗治疗全身性重症肌无力的比较

2022-05-31

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Neurology：利妥昔单抗治疗乙酰胆碱受体抗体阳性重症肌无力的2期试验：安全、耐受性良好，但不可显著减少类固醇使用

2022-03-15

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果

2022-06-02

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程

2022-02-23

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet Rheumatology: 利妥昔单抗对风湿性多肌痛患者的疗效：一项双盲、随机、安慰剂对照、概念验证试验

2022-03-25

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！

2022-02-06

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效

2022-10-31

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

BJD：超小剂量利妥昔单抗治疗天疱疮

2022-02-27

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Clin Cancer Res：利妥昔单抗+来那度胺→来那度胺治疗惰性非霍奇金淋巴瘤的长期预后

2022-05-24

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM:利妥昔单抗vs吗替麦考酚酯治疗中重度寻常型天疱疮

2021-12-07

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JASN：RI-CYCLO随机试验| 利妥昔单抗 vs 环磷酰胺治疗膜性肾病

2021-07-12

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效

2021-12-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JCEM：利妥昔单抗在治疗Graves眼病患者中没有获益？

2022-04-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效

2022-11-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

CRAL:天疱疮治疗指南的比较：全身糖皮质激素、利妥昔单抗和其他免疫抑制疗法

2022-02-03

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Cell：新生儿胆道闭锁发病机制被揭示，利妥昔单抗可能成为潜在治疗药物

2021-08-21

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫

2021-03-14

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Kidney Int：糖皮质激素和环磷酰胺交替治疗原发性膜性肾病优于他克莫司和利妥昔单抗的序贯治疗

2022-03-31

科室
- - 订阅+
  - 更多科室
工具
服务